使用泼尼松龙/皮质醇检测法判断重度哮喘患者对口服泼尼松龙的依从性
该研究评估了液相色谱-串联质谱(LC-MS/MS)检测血清泼尼松龙和皮质醇在判断重度哮喘患者口服泼尼松龙依从性中的效用。在吸收试验队列中,48%患者依从、48%不依从;在点测试队列中,40.3%患者不依从。不依从者皮质醇水平较高而泼尼松龙水平较低,且点测试可可靠识别不依从。
要点
- LC-MS/MS可检测血清泼尼松龙和皮质醇,用于判断重度哮喘患者口服泼尼松龙依从性。
- 点测试(可检测泼尼松龙且皮质醇受抑制)可在临床中可靠识别不依从。
- 不依从者皮质醇中位数较高、泼尼松龙较低,且BMI较低、血嗜酸性粒细胞较高。
核心结论
- 口服泼尼松龙不依从在重度哮喘中常见,可通过LC-MS/MS检测在临床中可靠识别。
研究设计与样本
- 泼尼松龙吸收试验纳入27例接受维持口服泼尼松龙的患者,平均年龄38.6岁,83%女性。
- 点测试队列纳入111例(67例维持泼尼松龙患者和44例对照),平均年龄42.4岁,79%女性。
- 采用验证过的LC-MS/MS assay测量血清泼尼松龙、皮质醇及代谢物水平。
主要发现
- 吸收试验中依从13例(48%)、不依从13例(48%)、吸收不良1例(3.7%)。
- 吸收试验依从组 vs 不依从组:皮质醇中位数36 vs 295 nmol/L,泼尼松龙中位数1,810 vs 1,730 nmol/L。
- 点测试队列中40.3%患者不依从;依从组 vs 不依从组皮质醇中位数27 vs 211 nmol/L,泼尼松龙中位数259 vs <20 nmol/L。
- 依从者平均BMI较高(38.4 ± 8.7 vs 32 ± 7.5 kg/m2;P = .03),血嗜酸性粒细胞中位数较低(0.09 vs 0.51 × 10^9/L;P < .001)。
- 依从者年严重急性发作次数有减少趋势(3.0 ± 2.6 vs 4.3 ± 2.4;P = .3)。
关键数值与推荐
- 点测试定义为可检测泼尼松龙且皮质醇受抑制,用于判断依从性。
临床怎么用
- 临床可采用LC-MS/MS点测试检测泼尼松龙和皮质醇,识别重度哮喘患者口服泼尼松龙不依从。
局限性
- 吸收试验样本量较小(27例),点测试队列中依从性判断的参考标准未在摘要中详述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonadherence to oral prednisolone is an important driver of poor control in severe asthma, and its detection is warranted to guide management. RESEARCH QUESTION: The goal of this study was to evaluate the utility of liquid chromatography and tandem mass spectrometry (LC-MS/MS) in determining the adherence status to oral prednisolone in severe asthma. STUDY DESIGN AND METHODS: Timeline serum levels of prednisolone, cortisol, and metabolites were measured by using a validated LC-MS/MS assay following observed intake of prednisolone in patients receiving maintenance oral prednisolone. Patterns of adherence and nonadherence were determined from analysis of peak blood levels. The performance of a spot test for adherence (detectable prednisolone and suppressed cortisol) was assessed in a second cohort of patients receiving maintenance prednisolone and a control group. RESULTS: In the prednisolone absorption test, 27 patients (mean age, 38.6 years; age range, 17-63 years; 83% female) were included. We identified adherence in 13 (48%), nonadherence in 13 (48%), and malabsorption in one (3.7%). The median [interquartile range] peak serum assays of the adherent group compared with the nonadherent group were: cortisol, 36 [39.5] vs 295 [153] nmol/L; and prednisolone, 1,810 [590] vs 1,730 [727] nmol/L. The spot test cohort included 111 patients (67 on maintenance prednisolone and 44 control subjects); the mean age was 42.4 years, and 79% were female. Nonadherence was detected in 40.3% of patients; comparison of the adherent vs nonadherent groups revealed median [interquartile range] levels for cortisol of 27 [48] nmol/L vs 211 [130] nmol/L and for prednisolone of 259 [622] nmol/L vs < 20 nmol/L, respectively. Adherent patients had higher mean BMI (38.4 ± 8.7 vs 32 ± 7.5 kg/m2; P = .03), lower median blood eosinophils (0.09 [0.31] vs 0.51 [0.53] × 109/L; P < .001), and a trend toward reduced mean annual severe exacerbations (3.0 ± 2.6 vs 4.3 ± 2.4; P = .3) than nonadherent patients. INTERPRETATION: Nonadherence to oral prednisolone is common in severe asthma and can be reliably detected in the clinic by using the LC-MS/MS assay.
引用
- Mansur AH, Hassan M, Duffy J, et al. Development and Clinical Application of a Prednisolone/Cortisol Assay to Determine Adherence to Maintenance Oral Prednisolone in Severe Asthma. Chest. 2020. PMID: 32298734. doi:10.1016/j.chest.2020.03.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。